Advanced Medicine

Demand for gene therapies is rising, so all the more reason to better understand the properties of their delivery devices

ISCT speaks out after US court rules that stem cell therapy does not fall under FDA jurisdiction.

Diversity, support networks, and unexpected journeys: what nine years of C&G biz wisdom can teach us

How can companies realistically incorporate patient-centric practices into cell and gene product development?

Can cell and gene therapy help bring an end to rare eye diseases?

ISCT’s new president talks platforms, regulation, and knowledge-transfer for the next generation

What happened at ISCT 2022’s return to in-person conferencing – and what can a new film release do for advanced therapy?

The International Society for Cell & Gene Therapy convened in person for the first time in two years. We spoke to an attendee for an insight

In our third C+G Champions installment, we ask industry leaders in the cell and gene field about accessibility for the many

The Medicine Maker and NIBRT present the Biopharma Trends Leaders’ Report 2022.